Fraunhofer Institute for Toxicology and Experimental MedicineNew Publication: RLS 0071, a Novel Anti-inflammatory Agent, Significantly Reduced Inflammatory Biomarkers in a Randomized Human Proof of Mechanism Study
Prof. Hohlfeld, division director of Airway Research at Fraunhofer ITEM, and his team provide important insights into the significance of RLS 0071 as a novel anti-inflammatory agent. In a randomized, double-blind, placebo-controlled clinical study they intended to translate RLS 0071 mechanism of action from animal disease models to humans.
Using inhaled LPS challenge in healthy volunteers #RLS0071 as a novel anti-inflammatory agent modulated neutrophil-mediated inflammation, consistent with results from prior animal model studies. The results also showed that RLS0071 was safe and well tolerated.
In cooperation with ReAlta Life Sciences and the German Centre for Lung Research (DZL, BREATH) the paper „RLS 0071, a Novel Anti-inflammatory Agent, Significantly Reduced Inflammatory Biomarkers in a Randomized Human Proof of Mechanism Study“ has been published in ERJ Open Research.
Authors
Kenji Cunnion1, 2, 3, 4, Jessica Goss1, Pamela Hair1, Linda Dell1, Destrey Roberson1, Ulrich Thienel1, Meike Mϋller5, 6, Saskia Carstensen-Aurèche5, 6, Philipp Badorrek5, Olaf Holz5, 6, Jens M. Hohlfeld5, 6, 7.
1ReAlta Life Sciences, Department of Research and Medical Affairs, Norfolk, VA USA
2Children’s Hospital of The King’s Daughters (CHKD), Norfolk, VA USA
3Children’s Specialty Group (CSG), Norfolk, VA USA
4Eastern Virginia Medical School (EVMS), Dept Paediatrics, Norfolk, VA USA
5Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Division of Airway Research, Hannover, Germany
6German Centre for Lung Research (DZL, BREATH), Hannover, Germany
7Hannover Medical School, Department of Respiratory Medicine and Infectious Disease, Hannover, Germany